Role of brain renin-angiotensin system in depression: A new perspective.

Autor: Ali NH; Department of Internal Medicine, Medical College, Najran University, Najran, KSA., Al-Kuraishy HM; Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq., Al-Gareeb AI; Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq., Albuhadily AK; Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq., Hamad RS; Biological Sciences Department, College of Science, King Faisal University, Al Ahsa, Saudi Arabia.; Central Laboratory, Theodor Bilharz Research Institute, Giza, Egypt., Alexiou A; University Centre for Research & Development, Chandigarh University, Mohali, Punjab, India.; Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.; AFNP Med, Wien, Austria., Papadakis M; Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Wuppertal, Germany., Saad HM; Department of Pathology, Faculty of Veterinary Medicine, Matrouh University, Matrouh, Egypt., Batiha GE; Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, AlBeheira, Egypt.
Jazyk: angličtina
Zdroj: CNS neuroscience & therapeutics [CNS Neurosci Ther] 2024 Apr; Vol. 30 (4), pp. e14525. Date of Electronic Publication: 2023 Nov 12.
DOI: 10.1111/cns.14525
Abstrakt: Depression is a mood disorder characterized by abnormal thoughts. The pathophysiology of depression is related to the deficiency of serotonin (5HT), which is derived from tryptophan (Trp). Mitochondrial dysfunction, oxidative stress, and neuroinflammation are involved in the pathogenesis of depression. Notably, the renin-angiotensin system (RAS) is involved in the pathogenesis of depression, and different findings revealed that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may be effective in depression. However, the underlying mechanism for the role of dysregulated brain RAS-induced depression remains speculative. Therefore, this review aimed to revise the conceivable role of ACEIs and ARBs and how these agents ameliorate the pathophysiology of depression. Dysregulation of brain RAS triggers the development and progression of depression through the reduction of brain 5HT and expression of brain-derived neurotrophic factor (BDNF) and the induction of mitochondrial dysfunction, oxidative stress, and neuroinflammation. Therefore, inhibition of central classical RAS by ARBS and ACEIs and activation of non-classical RAS prevent the development of depression by regulating 5HT, BDNF, mitochondrial dysfunction, oxidative stress, and neuroinflammation.
(© 2023 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje